<?xml version="1.0" encoding="UTF-8"?>
<p>No account of pharmacotherapy for viral infections would be complete without a mention of the numerous setbacks that have occurred. Right at the beginning of the “nucleoside era,” in the 1970s, it was recognized that cytarabine could not be used as a virustatic in disseminated herpes despite its high antiviral activity. Dissemination of the virus persisted for longer in the treatment group than in the placebo group (
 <xref rid="R15" ref-type="bibr">15</xref>). Decades later, the nucleosides fialuridine and clevudine were tested for possible use against hepatitis B. In both cases, the treatment had to be discontinued owing to toxicity with long-term intake, and research was abandoned (
 <xref rid="R16" ref-type="bibr">16</xref>, 
 <xref rid="R17" ref-type="bibr">17</xref>). Trials of various combinations for HIV infection were also discontinued because the treatments were insufficiently effective or poorly tolerated.
</p>
